Pmv Pharmaceuticals Inc (PMVP) - Total Liabilities
Based on the latest financial reports, Pmv Pharmaceuticals Inc (PMVP) has total liabilities worth $11.85 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore PMVP year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Pmv Pharmaceuticals Inc - Total Liabilities Trend (2018–2025)
This chart illustrates how Pmv Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data.
Pmv Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Pmv Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Trek Metals Ltd
AU:TKM
|
Australia | AU$488.17K |
|
Camus Engineering & Construction Inc
KO:013700
|
Korea | ₩185.93 Billion |
|
ZENTEK LTD.
F:ZAY0
|
Germany | €5.04 Million |
|
JCBNext Berhad Bhd
KLSE:0058
|
Malaysia | RM6.38 Million |
|
Shanghai Yaohua Pilkington Glass Group Co Ltd B
SHG:900918
|
China | $3.63 Billion |
|
GreenMobility A/S
CO:GREENM
|
Denmark | Dkr139.33 Million |
|
Aplex Technology
TWO:6570
|
Taiwan | NT$581.36 Million |
|
Ak Holdings
KO:006840
|
Korea | ₩4.85 Trillion |
Liability Composition Analysis (2018–2025)
This chart breaks down Pmv Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see PMVP market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.09 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Pmv Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Pmv Pharmaceuticals Inc (2018–2025)
The table below shows the annual total liabilities of Pmv Pharmaceuticals Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $11.85 Million | -22.08% |
| 2024-12-31 | $15.21 Million | -42.53% |
| 2023-12-31 | $26.46 Million | +8.99% |
| 2022-12-31 | $24.28 Million | +5.52% |
| 2021-12-31 | $23.01 Million | +258.95% |
| 2020-12-31 | $6.41 Million | -96.31% |
| 2019-12-31 | $173.51 Million | +58.31% |
| 2018-12-31 | $109.60 Million | -- |
About Pmv Pharmaceuticals Inc
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is rezatapopt, an orally available small molecule that potently and selectively correct p53 misfolding caused by p53 mutation, Y220C, while sparing wild-type p53. The company was formerly known as … Read more